Credit Suisse’s Clovis Oncology, Inc. CLVS Stock Holding History

Credit Suisse’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-50,000	Closed	-$521K	–	4322
2019 Q4	$521K	Hold	50,000	–	–	﹤0.01%	3541
2019 Q3	$197K	Hold	50,000	–	–	﹤0.01%	3867
2019 Q2	$744K	Hold	50,000	–	–	﹤0.01%	3151
2019 Q1	$1.24M	Hold	50,000	–	–	﹤0.01%	2715
2018 Q4	$898K	Hold	50,000	–	–	﹤0.01%	2867
2018 Q3	$1.47M	Hold	50,000	–	–	﹤0.01%	2579
2018 Q2	$2.27M	Hold	50,000	–	–	﹤0.01%	2345
2018 Q1	$2.64M	Buy	+50,000	New	+$2.92M	﹤0.01%	2199

Other funds holding CLVS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CAS

Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return

CASC

Coppell Advisory Solutions Corp Coppell, Texas $531M AUM

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

FFWM

Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Credit Suisse's CLVS Position: Q4 2022 in Review

Credit Suisse sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 46,952 shares — an estimated $56K sold.

Credit Suisse first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $16.8M in Q1 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

Credit Suisse reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
Credit Suisse sold 46,952 Clovis Oncology, Inc. shares in Q4 2022, an estimated $56K.
Credit Suisse first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
Credit Suisse's Clovis Oncology, Inc. position peaked at $16.8M in Q1 2017.
15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.